PH12022552457A1 - Liquid formulations of glucagon analogues - Google Patents
Liquid formulations of glucagon analoguesInfo
- Publication number
- PH12022552457A1 PH12022552457A1 PH1/2022/552457A PH12022552457A PH12022552457A1 PH 12022552457 A1 PH12022552457 A1 PH 12022552457A1 PH 12022552457 A PH12022552457 A PH 12022552457A PH 12022552457 A1 PH12022552457 A1 PH 12022552457A1
- Authority
- PH
- Philippines
- Prior art keywords
- glucagon analogues
- liquid formulations
- formulations
- dose
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20163408 | 2020-03-16 | ||
| PCT/EP2021/056651 WO2021185821A1 (en) | 2020-03-16 | 2021-03-16 | Liquid formulations of glucagon analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022552457A1 true PH12022552457A1 (en) | 2023-12-11 |
Family
ID=70008261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/552457A PH12022552457A1 (en) | 2020-03-16 | 2021-03-16 | Liquid formulations of glucagon analogues |
Country Status (23)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312600B2 (en) | 2022-05-30 | 2025-12-01 | Zealand Pharma As | Liquid formulations of amylin analogs |
| WO2025056677A1 (en) | 2023-09-15 | 2025-03-20 | Zealand Pharma A/S | Dasiglucagon for use in the treatment of congenital hyperinsulinism |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| WO2011117417A1 (en) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
| NZ704043A (en) * | 2012-07-23 | 2017-07-28 | Zealand Pharma As | Glucagon analogues |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| UA121874C2 (uk) | 2015-02-17 | 2020-08-10 | Елі Ліллі Енд Компані | Порошкова назальна композиція для лікування гіпоглікемії |
| WO2017053822A1 (en) | 2015-09-23 | 2017-03-30 | Behavioral Recognition Systems, Inc. | Detected object tracker for a video analytics system |
| GB201710822D0 (en) * | 2017-07-05 | 2017-08-16 | Zealand Pharma As | Methods and medical uses relating to the treatment of hypoglycaemia |
| WO2019110838A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
-
2021
- 2021-03-16 BR BR112022018462A patent/BR112022018462A2/pt unknown
- 2021-03-16 PH PH1/2022/552457A patent/PH12022552457A1/en unknown
- 2021-03-16 PE PE2022001968A patent/PE20230258A1/es unknown
- 2021-03-16 EP EP21712156.5A patent/EP4121003B1/en active Active
- 2021-03-16 HR HRP20251267TT patent/HRP20251267T1/hr unknown
- 2021-03-16 KR KR1020227031361A patent/KR102956482B1/ko active Active
- 2021-03-16 JP JP2022555741A patent/JP7834025B2/ja active Active
- 2021-03-16 HU HUE21712156A patent/HUE073401T2/hu unknown
- 2021-03-16 UA UAA202203796A patent/UA129439C2/uk unknown
- 2021-03-16 PL PL21712156.5T patent/PL4121003T3/pl unknown
- 2021-03-16 ES ES21712156T patent/ES3041327T3/es active Active
- 2021-03-16 US US17/203,126 patent/US20210283053A1/en not_active Abandoned
- 2021-03-16 WO PCT/EP2021/056651 patent/WO2021185821A1/en not_active Ceased
- 2021-03-16 MX MX2022011227A patent/MX2022011227A/es unknown
- 2021-03-16 CN CN202180021174.4A patent/CN115279341B/zh active Active
- 2021-03-16 IL IL295977A patent/IL295977A/en unknown
- 2021-03-16 RS RS20250960A patent/RS67245B1/sr unknown
- 2021-03-16 CA CA3171184A patent/CA3171184A1/en active Pending
- 2021-03-16 AR ARP210100659A patent/AR121581A1/es unknown
- 2021-03-16 TW TW110109431A patent/TW202200190A/zh unknown
- 2021-03-16 AU AU2021236878A patent/AU2021236878B2/en active Active
-
2022
- 2022-09-09 CL CL2022002472A patent/CL2022002472A1/es unknown
- 2022-10-11 CO CONC2022/0014452A patent/CO2022014452A2/es unknown
-
2024
- 2024-12-20 US US18/989,423 patent/US20250195424A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022011227A (es) | 2022-10-07 |
| CN115279341A (zh) | 2022-11-01 |
| EP4121003C0 (en) | 2025-08-06 |
| AU2021236878A1 (en) | 2022-09-29 |
| JP7834025B2 (ja) | 2026-03-23 |
| US20210283053A1 (en) | 2021-09-16 |
| HUE073401T2 (hu) | 2026-01-28 |
| HRP20251267T1 (hr) | 2025-12-05 |
| PE20230258A1 (es) | 2023-02-07 |
| KR102956482B1 (ko) | 2026-04-23 |
| BR112022018462A2 (pt) | 2022-11-01 |
| EP4121003A1 (en) | 2023-01-25 |
| TW202200190A (zh) | 2022-01-01 |
| AR121581A1 (es) | 2022-06-15 |
| WO2021185821A1 (en) | 2021-09-23 |
| CL2022002472A1 (es) | 2023-02-17 |
| PL4121003T3 (pl) | 2026-02-23 |
| JP2023518052A (ja) | 2023-04-27 |
| US20250195424A1 (en) | 2025-06-19 |
| KR20220154110A (ko) | 2022-11-21 |
| CA3171184A1 (en) | 2021-09-23 |
| ES3041327T3 (en) | 2025-11-11 |
| RS67245B1 (sr) | 2025-10-31 |
| AU2021236878B2 (en) | 2025-09-11 |
| CN115279341B (zh) | 2026-03-31 |
| NZ791927A (en) | 2025-09-26 |
| EP4121003B1 (en) | 2025-08-06 |
| UA129439C2 (uk) | 2025-04-23 |
| CO2022014452A2 (es) | 2022-10-21 |
| IL295977A (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210281A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr | |
| PE20242299A1 (es) | Composiciones agonistas de gip/glp1 | |
| MX2021004110A (es) | Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina. | |
| MX2022012359A (es) | Formulacion. | |
| MX2017003102A (es) | Formulacion para inhalacion liquida que comprende rpl554. | |
| PH12015502539B1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| BRPI0908887A2 (pt) | composição farmacêutica líquida, recipiente farmacêutico, métodos para preparar e para fabricar uma composição farmacêutica, e, uso de uma composição farmacêutica | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| AR087003A1 (es) | Dispositivo separador modular para el tratamiento de infecciones de la protesis de miembros humanos | |
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| MX380361B (es) | Suspensiones orales fisica y quimicamente estables de givinostat. | |
| CO6220945A2 (es) | Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma | |
| CL2022002472A1 (es) | Formulaciones líquidas de análogos de glucagón | |
| EA201400484A1 (ru) | Трансдермальное средство для лечения и профилактики болезней суставов и мягких тканей | |
| SG10201807034XA (en) | A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease | |
| EP4696381A3 (en) | Medicine | |
| JP7164976B2 (ja) | 外用医薬組成物 | |
| MX381515B (es) | Composición farmacéutica que comprende nebivolol con tasa de disolución mejorada | |
| RU2018108842A (ru) | Способ лечения заболевания с использованием соединения, оказывающего воздействие на гликолиз | |
| JP7186026B2 (ja) | 外用医薬組成物 | |
| MX2022000968A (es) | Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio. | |
| MX393290B (es) | Composicion para el tratamiento de la osteoartritis | |
| ZA202200330B (en) | Pharmaceutical composition of imatinib | |
| WO2020227465A3 (en) | Methods for preparing stable dna compositions | |
| UA123399U (uk) | Фармацевтична композиція холіну альфосцерату у лікарській формі для орального застосування |